Advances in Therapy

, 25:858 | Cite as

Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis

  • Jodi LuchsEmail author
Original Research



Azithromycin, a broad-spectrum antibiotic with potent anti-inflammatory activities, has the potential to effectively treat blepharitis, an inflammatory disease of the eyelid with abnormal eyelid flora as an etiologic determinant. The present study compared the efficacy of topical azithromycin ophthalmic solution 1% (AzaSite®; Inspire Pharmaceuticals, Inc, NC, USA) combined with warm compresses (azithromycin group) to warm compresses alone (compress group) in patients with posterior blepharitis.


Twenty-one patients diagnosed with posterior blepharitis were randomized in an open-label study to receive either azithromycin plus warm compresses (10 patients), or compresses alone (11 patients). All patients were instructed to apply compresses to each eye for 5–10 minutes twice daily for 14 days. Each eye in the azithromycin group also received azithromycin solution (1 drop) twice daily for the first 2 days followed by once daily for the next 12 days. Patients were evaluated at study initiation (visit 1) and at end of treatment (visit 2) for the severity of five clinical signs: eyelid debris, eyelid redness, eyelid swelling, meibomian gland (MG) plugging, and the quality of MG secretion. At visit 2, patients also rated their degree of overall symptomatic relief.


Twenty patients completed the study. At visit 2, patients in the azithromycin group demonstrated significant improvements in MG plugging, MG secretions, and eyelid redness as compared with the compress group. In the azithromycin group, MG plugging resolved completely in three patients and MG secretion returned to normal in two patients; no such results were seen in the compress group. Furthermore, a higher percentage of patients in the azithromycin group rated overall symptomatic relief as excellent or good. Visual acuity measurements and biomicroscopic evaluation revealed no ocular safety issues.


Azithromycin ophthalmic solution in combination with warm compresses provided a significantly greater clinical benefit than warm compresses alone in treating the signs and symptoms of posterior blepharitis.


AzaSite meibomian gland posterior blepharitis topical azithromycin warm compresses 


  1. 1.
    Jackson WB. Blepharitis: current strategies for diagnosis and management. Can J Ophthalmol. 2008;43:170–179.PubMedCrossRefGoogle Scholar
  2. 2.
    Smith RE, Flowers CW Jr. Chronic blepharitis: a review. CLAO J. 1995;21:200–207.PubMedGoogle Scholar
  3. 3.
    Foulks GN, Bron AJ. Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. Ocul Surf. 2003;1:107–126.PubMedGoogle Scholar
  4. 4.
    McCulley JP, Dougherty JM. Bacterial aspects of chronic blepharitis. Trans Ophthalmol Soc U K. 1986;105:314–318.PubMedGoogle Scholar
  5. 5.
    Dougherty JM, McCulley JP. Comparative bacteriology of chronic blepharitis. Br J Ophthalmol. 1984;68:524–528.PubMedCrossRefGoogle Scholar
  6. 6.
    Dougherty JM, McCulley JP. Bacterial lipases and chronic blepharitis. Invest Ophthalmol Vis Sci. 1986;27:486–491.PubMedGoogle Scholar
  7. 7.
    Seal D, Ficker L, Ramakrishnan M, Wright P. Role of staphylococcal toxin production in blepharitis. Ophthalmology. 1990;97:1684–1688.PubMedGoogle Scholar
  8. 8.
    Mondino BJ, Caster AI, Dethlefs B. A rabbit model of staphylococcal blepharitis. Arch Ophthalmol. 1987;105:409–412.PubMedGoogle Scholar
  9. 9.
    Ficker L, Ramakrishnan M, Seal D, Wright P. Role of cell-mediated immunity to staphylococci in blepharitis. Am J Ophthalmol. 1991;111:473–479.PubMedGoogle Scholar
  10. 10.
    Yanoff M, Fine B. Ocular Pathology. Philadelphia, PA: J. B. Lippincott; 1989.Google Scholar
  11. 11.
    Friedlaender MH, Protzko E. Clinical development of 1% azithromycin in DuraSite, a topical azalide anti-infective for ocular surface therapy. Clin Ophthalmol. 2007;1:3–10.PubMedGoogle Scholar
  12. 12.
    Amsden GW. Anti-inflammatory effects of macrolides—an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother. 2005;55:10–21.PubMedCrossRefGoogle Scholar
  13. 13.
    Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents. 2008;31:12–20.PubMedCrossRefGoogle Scholar
  14. 14.
    Culic O, Erakovic V, Cepelak I, et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol. 2002;450:277–289.PubMedCrossRefGoogle Scholar
  15. 15.
    Ferris FL 3rd, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol. 1982;94:91–96.PubMedGoogle Scholar
  16. 16.
    Early Treatment Diabetic Retinopathy Study Research Group. Early treatment diabetic retinopathy study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology. 1991;98:741–756.Google Scholar
  17. 17.
    Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther. 2005;27:1329–1342.PubMedCrossRefGoogle Scholar
  18. 18.
    Groden LR, Murphy B, Rodnite J, Genvert GI. Lid flora in blepharitis. Cornea. 1991;10:50–53.PubMedCrossRefGoogle Scholar
  19. 19.
    Seal DV, McGill JI, Jacobs P, Liakos GM, Goulding NJ. Microbial and immunological investigations of chronic non-ulcerative blepharitis and meibomianitis. Br J Ophthalmol. 1985;69:604–611.PubMedCrossRefGoogle Scholar
  20. 20.
    Bron AJ, Tiffany JM. The contribution of meibomian disease to dry eye. Ocul Surf. 2004;2:149–165.PubMedGoogle Scholar
  21. 21.
    McCulley JP, Shine WE. The lipid layer of tears: dependent on meibomian gland function. Exp Eye Res. 2004;78:361–365.PubMedCrossRefGoogle Scholar
  22. 22.
    Song PI, Abraham TA, Park Y, et al. The expression of functional LPS receptor proteins CD14 and toll-like receptor 4 in human corneal cells. Invest Ophthalmol Vis Sci. 2001;42:2867–2877.PubMedGoogle Scholar
  23. 23.
    Dougherty JM, McCulley JP, Silvany RE, Meyer DR. The role of tetracycline in chronic blepharitis. Inhibition of lipase production in staphylococci. Invest Ophthalmol Vis Sci. 1991;32:2970–2975.PubMedGoogle Scholar
  24. 24.
    Yoon KC, Jeong IY, Park YG, Yang SY. Interleukin-6 and tumor necrosis factoralpha levels in tears of patients with dry eye syndrome. Cornea. 2007;26:431–437.PubMedCrossRefGoogle Scholar
  25. 25.
    Barton K, Monroy DC, Nava A, Pflugfelder SC. Inflammatory cytokines in the tears of patients with ocular rosacea. Ophthalmology. 1997;104:1868–1874.PubMedGoogle Scholar
  26. 26.
    Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Pro-and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci. 2001;42:2283–2292.PubMedGoogle Scholar
  27. 27.
    Afonso AA, Sobrin L, Monroy DC, Selzer M, Lokeshwar B, Pflugfelder SC. Tear fluid gelatinase B activity correlates with IL-1alpha concentration and fluorescein clearance in ocular rosacea. Invest Ophthalmol Vis Sci. 1999;40:2506–2512.PubMedGoogle Scholar
  28. 28.
    Perry HD, Doshi-Carnevale S, Donnenfeld ED, Solomon R, Biser SA, Bloom AH. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea. 2006;25:171–175.PubMedCrossRefGoogle Scholar
  29. 29.
    Rubin M, Rao SN. Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis. J Ocul Pharmacol Ther. 2006;22:47–53.PubMedCrossRefGoogle Scholar
  30. 30.
    Kunert KS, Tisdale AS, Stern ME, Smith JA, Gipson IK. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol. 2000;118:1489–1496.PubMedGoogle Scholar

Copyright information

© Springer Healthcare Communications 2008

Authors and Affiliations

  1. 1.Department of Ophthalmology and Visual SciencesAlbert Einstein College of MedicineBronxUSA
  2. 2.Department of Refractive SurgeryNorth Shore/Long Island Jewish Health SystemGreat NeckUSA

Personalised recommendations